Members Login Join NHIVNA
 
Patrons Executive Committee Subcommittees & Working Groups Objectives and Powers Annual Report & Accounts Membership
You are here: > News

Featured NHIVNA news

HIV Nursing 2017
by NHIVNA Admin, 2017-06-17 10:55

National Standards of Peer Support in HIV launched
by NHIVNA Admin, 2017-06-15 10:05

Advanced Nursing practice in HIV care: Guidelines for nurses, doctors, service providers and commissioners
by NHIVNA Admin, 2016-08-18 09:20


Other latest news

Peripheral artery disease more common in people with HIV with lower CD4 counts
by Keith Alcorn, 2017-08-15 14:40
Peripheral artery disease, one of the most common forms of cardiovascular disease, occurs more frequently in people with HIV who have CD4 cell counts below 500, regardless of whether they smoke or have other risk factors for cardiovascular disease, an analysis of the large US Veterans Aging Cohort Study has

PrEP use in US exceeds 100,000 in Gilead pharmacy survey
by Liz Highleyman, 2017-08-14 12:50
An estimated 120,000 people in the US have started Truvada for pre-exposure prophylaxis (PrEP) since 2012, according to the latest findings from a survey of retail and mail-order pharmacies by Gilead Sciences. The new numbers, presented at the 9th International AIDS Society Conference on HIV Science (IAS 2017) last month in

Incidence of anal cancer has already peaked among HIV-positive gay men; reductions can be achieved with expanded ART coverage and screening
by Michael Carter, 2017-08-11 12:30
The incidence of anal cancer among HIV-positive gay men peaked in 2009 and will decline substantially by 2030, even with current levels of antiretroviral therapy (ART) coverage and no cancer-screening programme, Swiss investigators report in AIDS. Further significant reductions would be achieved with 100% treatment coverage and various screening strategies.

Treatment with DAAs reduces the risk of mortality in the first 18 months after the completion of treatment
by Michael Carter, 2017-08-10 12:50
For the first time, a large study has demonstrated that treatment with direct-acting antivirals (DAAs) significantly reduces mortality rates among people with hepatitis C virus (HCV) monoinfection. The study – published in Clinical Infectious Diseases – matched people who received therapy with all-DAA regimens with untreated controls. Mortality rates in



Source: www.aidsmap.com
© Copyright National HIV Nurses Association (NHIVNA) 2017
     Registered Charity Number 1099074